• Strategy
  • Payers
  • AI
  • Cybersecurity
  • Device Development
  • Studies/Published Research
  • Ethics
  • Regulatory
  • Digital Biomarkers
  • Data Science
  • Companion Diagnostics
  • Clinical Care
  • Digital Therapeutics
  • Academic Research
  • Virtual Reality
  • RWE
  • Digital Endpoints
  • Medical Devices (Class II and Class III)
  • Commercialization
  • Clinical Trials
  • Drug-Device Combinations
  • SaMD
  • Remote Patient Monitoring
  • Patient Engagement
  • Profiles/Q&A

HealthVerity Launches Software to Help Synchronize Pharmaceutical Product Lifecycle


The software, named Health Verity FLOW, will integrate data from real-world examples, clinical trials, and other registries for pharmaceutical manufacturers.

HealthVerity announced the launch of HealthVerity FLOW, a pharma-class Software-as-a-Service solution that enables pharmaceutical manufacturers to integrate extensive real-world data capabilities with patient-centric compliance across the full spectrum of registries, clinical trials, and commercial activities. HealthVerity FLOW provides an option for data-driven companies seeking to unify and accelerate the process for building more comprehensive patient journeys in a highly accurate, privacy protecting manner, while also ensuring that data rights and data management are governed uniformly across the enterprise.

Pharmaceutical companies have traditionally invested billions of dollars in registries and clinical trials to collect first-party data from patients on a blinded basis. This technique insulated sponsors from more complex data compliance issues, but ultimately limited the speed and quality of patient analytics that could be conducted in advance of initial regulatory submissions or applications for new indications. Advances in data science, however, combined with the breadth of HIPAA-compliant data now available, have prompted a movement by market leaders to seek approval from Institutional Review Boards (IRBs) to benefit from these trends. This is further supported by regulatory agencies that are increasingly more accepting of RWD, with appropriate provenance, as an important component in regulatory filings. Despite the momentum, companies are struggling with the burdens of effectively managing patient permissions, discovering and sourcing third-party patient data, governing the exchange of data between sources and researchers, and managing the complex workflows across numerous registries, clinical trials and commercial initiatives.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.